EU GMP Certification Achieved By Mubadala Bio's Bioventure Healthcare

Mubadala Bio announced that subsidiary Bioventure Healthcare has gained European Union Good Manufacturing Practice certification, following strict on-site inspections. The approval allows continued export of medicines to EU markets and supports wider international access. The UAE facility now joins a small group of domestic manufacturers holding this certification for pharmaceutical production.

The new status supports Mubadala Bio’s wider growth agenda in pharmaceutical manufacturing and distribution. It backs national plans to develop a health industry that follows global benchmarks while offering innovative treatments. EU GMP certification is therefore both a compliance milestone and a strategic tool for long-term expansion.

EU GMP certification confirms that Bioventure Healthcare follows strict European rules for medicine quality, safety and consistency. These standards guide how products are produced, checked and documented. Meeting them helps ensure that patients receive medicines that are reliable and effective, while regulators and partners have confidence in the company’s operations.

The recognition supports Mubadala Bio’s mission to deliver better health solutions for the UAE and other markets. It enables faster entry into new territories and greater participation in global supply chains. The achievement also highlights ongoing work to improve resilience in healthcare systems through strong regional manufacturing capacity.

Bioventure Healthcare runs a 23,000 square-metre facility that produces soft gel capsules for pharmaceutical products. The site has an annual capacity of 1.5 billion capsules, making it the region’s largest producer in this category. This scale supports both domestic demand and export opportunities connected to the EU GMP certification.

The facility includes modern production lines, blister and bottle packaging, no-fill detection systems and serialisation with track-and-trace. A full quality control and microbiology laboratory oversees testing and compliance. These systems help maintain product safety and reliability, and position Bioventure Healthcare as a key supplier of medicines and supplements across the region.

Leadership views on EU GMP certification for Mubadala Bio and Bioventure Healthcare

Dr. Essam Mohamed, CEO of Mubadala Bio, said, "This certification reinforces Bioventure Healthcare’s capabilities in delivering advanced, high-quality pharmaceutical products. It also reflects Mubadala Bio’s commitment to strengthening healthcare resilience and advancing local capabilities in the sector." The comments underline how the approval supports both corporate and national healthcare objectives.

Deputy CEO Hamad Al Marzooqi added, "Securing EU GMP certification reflects our commitment to delivering better health, closer for all. It not only reinforces our ability to expand our global footprint and build trust in our products worldwide but also strengthens our role as a trusted partner in the life sciences sector."

By combining EU GMP certification with large-scale capsule production and advanced quality systems, Mubadala Bio and Bioventure Healthcare strengthen their position in regional and global markets. The development supports the UAE’s healthcare ambitions and provides a stronger base for supplying consistent, high-quality medicines and supplements to patients in the Middle East and beyond.

With inputs from WAM